FEIBA (factor eight inhibitor bypassing activity) for hemophilia
FEIBA is an approved treatment for patients with hemophilia A and B, some of whom may have stopped responding to replacement therapy.
FEIBA is an approved treatment for patients with hemophilia A and B, some of whom may have stopped responding to replacement therapy.
Health Canada has approved the gene therapy Hemgenix (etranacogene dezaparvovec) for treating adults with hemophilia B who rely on routine prophylactic therapies to prevent or reduce bleeding episodes. Hemgenix is now the first and only gene therapy available to this patient group. “The approval of Hemgenix in Canada…
Read about Esperoct, an extended half-life infusion treatment approved to prevent or stop bleeding in children and adults with hemophilia A.
The recent Rare Blood Disease Summit sponsored by Genentech highlighted a critical perspective pertinent to me: “Mild is the most dangerous word in hemophilia.” I wholeheartedly agree with this statement as a person with mild hemophilia B and von Willebrand disease. Mild hemophilia is distinguished…
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.
People with hemophilia are living longer, but Black males still are more likely to die from the disease, and at a younger age, compared with white people, a U.S. study finds. More research is needed to understand the reason for this difference and to improve care and survival rates…
Although no cure for hemophilia is currently available, a number of therapies can be used to control bleeding and other symptoms. These treatments can substantially increase life expectancy by lowering the risk of life-threatening complications such as bleeding in the brain, especially in people with severe hemophilia.
Hemophilia is a disorder wherein the blood is not able to clot properly. As a result, patients bleed easily, and it's unusually prolonged and heavy.
Hemophilia is a rare disorder in which the blood doesn’t clot properly, resulting in the disease’s hallmark symptoms of bleeds — excessive bleeding that extends over a prolonged period of time — that in turn leads to other complications.
A global survey of more than 2,700 hemophilia patients, caregivers, and healthcare providers, which aimed to uncover the daily challenges of living with the rare blood disorder or caring for those who do, found that many patients regularly hide their symptoms — including from their doctors. “More than…
Get regular updates to your inbox.